Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Teva
Farmers Insurance
Queensland Health
Harvard Business School
Healthtrust
Medtronic
Accenture
Moodys
Fish and Richardson
Dow

Generated: October 19, 2017

DrugPatentWatch Database Preview

VIZAMYL Drug Profile

« Back to Dashboard

What is the patent landscape for Vizamyl, and what generic Vizamyl alternatives are available?

Vizamyl is a drug marketed by Ge Healthcare and is included in one NDA. There are five patents protecting this drug.

This drug has seventy-six patent family members in twenty-three countries and eighteen supplementary protection certificates in twelve countries.

The generic ingredient in VIZAMYL is flutemetamol f-18. One supplier is listed for this compound. Additional details are available on the flutemetamol f-18 profile page.

Summary for Tradename: VIZAMYL

US Patents:5
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list1
Clinical Trials: see list3
Patent Applications: see list14
Drug Prices:see details
DailyMed Link:VIZAMYL at DailyMed

Pharmacology for Tradename: VIZAMYL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ge Healthcare
VIZAMYL
flutemetamol f-18
INJECTABLE;INTRAVENOUS203137-001Oct 25, 2013RXYesYes► Subscribe► SubscribeYY ► Subscribe
Ge Healthcare
VIZAMYL
flutemetamol f-18
INJECTABLE;INTRAVENOUS203137-002Oct 25, 2013RXYesYes► Subscribe► SubscribeYY ► Subscribe
Ge Healthcare
VIZAMYL
flutemetamol f-18
INJECTABLE;INTRAVENOUS203137-001Oct 25, 2013RXYesYes► Subscribe► SubscribeYY ► Subscribe
Ge Healthcare
VIZAMYL
flutemetamol f-18
INJECTABLE;INTRAVENOUS203137-002Oct 25, 2013RXYesYes► Subscribe► Subscribe► Subscribe
Ge Healthcare
VIZAMYL
flutemetamol f-18
INJECTABLE;INTRAVENOUS203137-002Oct 25, 2013RXYesYes► Subscribe► Subscribe ► Subscribe
Ge Healthcare
VIZAMYL
flutemetamol f-18
INJECTABLE;INTRAVENOUS203137-001Oct 25, 2013RXYesYes► Subscribe► Subscribe ► Subscribe
Ge Healthcare
VIZAMYL
flutemetamol f-18
INJECTABLE;INTRAVENOUS203137-001Oct 25, 2013RXYesYes► Subscribe► SubscribeYY ► Subscribe
Ge Healthcare
VIZAMYL
flutemetamol f-18
INJECTABLE;INTRAVENOUS203137-001Oct 25, 2013RXYesYes► Subscribe► Subscribe► Subscribe
Ge Healthcare
VIZAMYL
flutemetamol f-18
INJECTABLE;INTRAVENOUS203137-001Oct 25, 2013RXYesYes► Subscribe► SubscribeY ► Subscribe
Ge Healthcare
VIZAMYL
flutemetamol f-18
INJECTABLE;INTRAVENOUS203137-002Oct 25, 2013RXYesYes► Subscribe► SubscribeYY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: VIZAMYL

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,854,920Thioflavin derivatives for use in antemortem diagnosis of alzheimer's disease and in vivo imaging and prevention of amyloid deposition► Subscribe
8,911,707Thioflavin derivatives for use in antemortem diagnosis of alzheimer's disease and in vivo imaging and prevention of amyloid deposition► Subscribe
9,134,328Methods of using benzothiazole derivative compounds and compositions► Subscribe
8,404,213Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: VIZAMYL

Country Document Number Estimated Expiration
China1285582► Subscribe
China102532055► Subscribe
Denmark1611115► Subscribe
Japan2012102106► Subscribe
Australia2011200667► Subscribe
Hong Kong1086270► Subscribe
Norway2015005► Subscribe
Russian Federation2440995► Subscribe
European Patent Office1611115► Subscribe
Spain2464715► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: VIZAMYL

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2015000017Germany► SubscribePRODUCT NAME: FLUTEMETAMOL (18F) IN ALLEN DEM SCHUTZ DES GRUNDPATENTS UNTERLIEGENDEN FORMEN; REGISTRATION NO/DATE: EU/1/14/941 20140822
C0005France► SubscribePRODUCT NAME: FLUTEMETAMOL (18 F); REGISTRATION NO/DATE: EU/1/14/941 20140822
634Luxembourg► SubscribePRODUCT NAME: FLUTEMETAMOL (18F) ET SES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES (VIZAMYL). FIRST REGISTRATION: 20140826
2015 00008Denmark► SubscribePRODUCT NAME: RADIOAKTIVE ISOTOPER AF FLUTEMETAMOL, SAERLIGT FLUTEMETAMOL (18F); REG. NO/DATE: EU/1/14/941 20140822
90009-5Sweden► SubscribePRODUCT NAME: FLUTEMETAMOL (18F); REG. NO/DATE: EU/1/14/941 20140826
15006Norway► SubscribePRODUCT NAME: VIZAMYL; REG. NO/DATE: EU/1/14/941 20140822
0150004 00139Estonia► SubscribePRODUCT NAME: FLUTEMETAMOOL (18F);REG NO/DATE: EU/1/14/941 26.08.2014
00724Netherlands► SubscribePRODUCT NAME: FLUTEMETAMOL (18 F); REGISTRATION NO/DATE: EU/1/14/941 20140822
3 5003-2015Slovakia► SubscribePRODUCT NAME: FLUTEMETAMOL (18F); REGISTRATION NO/DATE: EU/1/14/941 20140822
2015Austria► SubscribePRODUCT NAME: (18F) - FLUTEMETAMOL; REGISTRATION NO/DATE: EU/1/14/941 (MITTEILUNG) 20140826
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

UBS
Johnson and Johnson
Covington
US Army
US Department of Justice
Accenture
Healthtrust
Moodys
Cipla
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot